03069 ChinaAMC Hang Seng
- 8.010
- -0.005-0.06%
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.
Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally
Summit Therapeutics fell nearly 20% Tuesday as the biotech firm's stock continued to give back part of a 280%+ rally that it saw last Thursday on positive study results for its candidate cancer drug ivonescimab.
Did Kang Fang Bio, which collapsed in the past, turn around with “head to head” with K medicine?
Investing in health requires a strong heart.
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lym
AH stocks continued to consolidate, biomedical and real estate stocks plummeted, and Kangfang Biotech plummeted 24%
On the market, sectors such as coal, utilities, environmental protection, agriculture, forestry, animal husbandry and fishing, petroleum and petrochemicals, and basic chemicals registered the highest gains, while real estate, non-ferrous metals, defense and military, beauty and care, household appliances, and power equipment weakened.
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
BeiGene GAAP EPADS of -$2.41 Beats by $0.48, Revenue of $751.65M Beats by $76.42M
BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $(2.89) Estimate, Sales $751.652M Beat $676.451M Estimate
BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16.61 percent. This is a 27.84 percent increase over losses of $(3.34) per
Evaluating BeiGene: Insights From 6 Financial Analysts
In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick overview of
EU Regulators Approve BeiGene's Tislelizumab for Lung Cancer
2023 年度報告
4 Analysts Assess BeiGene: What You Need To Know
4 Analysts Assess BeiGene: What You Need To Know
Giant Biotech's net profit increased by 44.9% in '23, but there are still two problems in the medium to long term | Insight Research
Looking at cosmetics in the short term and relying on medical beauty for the long term?
Kangfang Biotech is refinancing in the middle of the winter | Insight Research
What does refinancing $1.1 billion mean for existing shareholders?
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
On Thursday, the FDA approved BeiGene Ltd's (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ES
BeiGene Secures FDA Approval For TEVIMBRA For Treatment Of Advanced Or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
TEVIMBRA will be available in the U.S. in the second half of 2024. The FDA is also reviewing Biologics License Applications (BLAs) for tislelizumab as a first-line treatment for patients with unresect
BeiGene Gains as Access to Leukemia Drug Brukinsa Expands
BeiGene's ADR once rose 13%, and the company announced the first dose of leukemia treatment for patients
BeiGene's ADR once rose 13%, the biggest intraday increase since April 2023. Earlier, the biotech company announced that the first dose of Brukinsa has been used to treat adult patients with chronic lymphocytic leukemia. Patients from Armenia and Nepal were among the first 29 countries to be treated with Brukinsa as part of a three-year cooperative project to provide the drug to 29 low- and middle-income countries. (Continuously updated...)
KB Financial, BeiGene, Legend Biotech Among Premarket Gainers' Pack
First Doses Of BRUKINSA Provided To Patients With Chronic Lymphocytic Leukemia In Low- And Middle-Income Countries Under Collaboration Of Max Foundation, BeiGene And BeiGene Foundation
Armenia and Nepal are the first of 29 countries to receive BRUKINSA